

To: [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@erasmusmc.nl; [redacted]@erasmusmc.nl
Cc: [redacted]@rivm.nl
From: [redacted]
Sent: Mon 3/8/2021 5:26:03 PM
Subject: FW: Eurosurveillance FINAL edited draft for checking and approval and designed Figures MS 20-01134
Received: Mon 3/8/2021 5:26:07 PM
[FINAL_20-01134](#); [redacted] [Molecular testing ForApproval.docx](#)
[Reusken-Fig.1.png](#)
[Reusken-Fig.2.png](#)
[Reusken-Fig.3.png](#)

Dear all,

Please find attached the final version of our COVID-19 review before publication in Eurosurveillance.

I checked the last edits and all looks ok. Please let us (me or [redacted]) know that you have seen and approve the final version for publication by Wednesday 10 March.

Kind regards,

[redacted]

[redacted], [redacted], [redacted]

European Public Health Microbiology (EUPHEM) fellow

National Institute for Public Health and the Environment (RIVM)

Antonie van Leeuwenhoeklaan 9 | 3720 MA Bilthoven | The Netherlands

T: [redacted]
M: [redacted]
E: [redacted]@rivm.nl
I: <http://www.rivm.nl>

From: [redacted] <[redacted]@ecdc.europa.eu>
Sent: 08 March 2021 17:52
To: [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>
Subject: Eurosurveillance FINAL edited draft for checking and approval and designed Figures MS 20-01134

Dear [redacted] and [redacted],

Attached you will find the FINAL edited version of your manuscript.

- There are minor edits in the text.
- For the references, I have edited some of these, by checking against the original manuscripts online (through the doi). Please carefully check the edits.

I hereby kindly invite you to please thoroughly check this final edited version to make sure it is all right and to please ensure that all authors of the manuscript see the final edited version.

The designer has now recreated the Figures of your manuscript in our journal style. These are included in the manuscript text, but I also enclose them separately with this message for your consideration. Please carefully check the Figures attached to make sure they are all correct and that no mistake unintentionally occurred during the design process. For Figure 1 there are some comments in the manuscript as this one is a bit different from your original.

If everything is fine with the final edited manuscript text, please let us know, in the answer to this email, that **all authors have seen and approve the final edited version of the text for publication. We need this statement from you to be able to publish.**

For the Figures, if there are any change requests, please let us know as soon as possible. We can do any needed changes to the Figures in parallel to all authors checking the manuscript text.

If possible, we would prefer for you to get back to us regarding the approval of the final version by the end of the day on Wednesday 10 March, however if you need more time, just please do keep us informed so we can prepare/plan accordingly.

Kind regards,

5.1.2e

From: EUROSURVEILLANCE
Sent: 08 March 2021 16:11
To: 5.1.2e <5.1.2e@rivm.nl>
Cc: 5.1.2e <5.1.2e@rivm.nl>
Subject: Eurosurveillance update: will send a final edited version today for you to check MS 20-01134

Dear 5.1.2e

I hope you are well. I have worked on your manuscript today, and the designer has recreated the Figures in our journal style. I am currently editing a few references in the reference list, but will thereafter will send you the next version and designed Figures, so that you have these today. I will be in touch shortly.

Kind regards,

5.1.2e

From: 5.1.5 <5.1.2e@ecdc.europa.eu>
Sent: 03 March 2021 12:06
To: 5.1.2e <5.1.2e@rivm.nl>
Cc: 5.1.2e <5.1.2e@rivm.nl>
Subject: RE: Eurosurveillance update on your manuscript MS 20-01134

Thanks.

All seems sorted. We will clean now and Karen will take over and should be able to send the final for approval on Monday if all goes as planned.

All the best

5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: 03 March 2021 11:36
To: 5.1.2e <5.1.2e@ecdc.europa.eu>
Cc: 5.1.2e <5.1.2e@rivm.nl>; 5.1.5 <5.1.2e@ecdc.europa.eu>
Subject: RE: Eurosurveillance update on your manuscript MS 20-01134

EXTERNAL EMAIL - Do not click on any links, open attachments or reply, unless you recognise the sender's email address (5.1.2e@rivm.nl) and believe the content is safe.

Dear 5.1.2e

We hope you are feeling better and fully recovered.

Thank you for the prefinal version, please find our corrections and comments attached.

Our co-authors know that we are in the pre-publication stage, so though busy, hopefully will respond right away to the approval request.

Kind regards,

5.1.2e

5.1.2e 5.1.2e 5.1.2e
European Public Health Microbiology (EUPHEM) fellow

National Institute for Public Health and the Environment (RIVM)
Antonie van Leeuwenhoeklaan 9 | 3720 MA Bilthoven | The Netherlands

T 5.1.2e

M [redacted] 5.1.2e
 E [redacted] 5.1.2e @rivm.nl
 I <http://www.rivm.nl>

From: [redacted] 5.1.2e <[redacted] 5.1.2e @ecdc.europa.eu>
Sent: 02 March 2021 18:27
To: [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Cc: [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.5 <[redacted] 5.1.2e @ecdc.europa.eu>
Subject: RE: Eurosurveillance update on your manuscript MS 20-01134

Dear [redacted] 5.1.2e and [redacted] 5.1.2e

Sorry that I was not able to get back to you earlier. I was off sick last Friday and not able to work on the weekend so still trying to catch up.

I attach a version of your manuscript with another round of edits/point for clarifications from me and [redacted] 5.1.2e. There are not many and they should be easy to address. After this round we may be able to prepare a final for approval. There will be minor changes to the figures [redacted] 5.1.2e will handle them when she is back from leave next week on Monday.

Meanwhile we can continue to work on the text and you can already line up the co-authors for their approval next week if possible by Wednesday so we can publish on Thursday – what do you think?

Kind regards

[redacted] 5.1.2e



[redacted] 5.1.2e
 [redacted] 5.1.2e
 [redacted] 5.1.2e
 Phone [redacted] 5.1.2e
 [redacted] 5.1.2e @ecdc.europa.eu

Eurosurveillance
Published by European Centre for Disease
Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden
 Phone + [redacted] 5.1.2e / Fax +46 (0)8 58 60 10 01
www.eurosurveillance.org

Follow Eurosurveillance on:



From: [redacted] 5.1.5 <[redacted] 5.1.2e @ecdc.europa.eu>
Sent: 26 February 2021 09:53
To: [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Cc: [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Subject: Eurosurveillance update on your manuscript MS 20-01134

Dear [redacted] 5.1.2e

I have made progress going through the manuscript and this is now with the Editor-in-chief, according to our routines, for checking. We will get back to you as soon as possible regarding the manuscript, but there may be a delay, as the Editor-in-chief is not well today.

Looking forward to being further in contact, I wish you and [redacted] 5.1.2e in the meantime a nice weekend.

Kind regards,

[redacted] 5.1.2e

From: EUROSURVEILLANCE
Sent: 24 February 2021 16:25
To: [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>

Cc: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Subject: RE: Eurosurveillance update request MS 20-01134

Dear 5.1.2e
Many thanks for your email with the documents, which I confirm receiving.
We will go through these and get back to you as soon as possible.
Kind regards,
5.1.2e

From: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Sent: 24 February 2021 16:18
To: 5.1.5 <5.1.2e @ecdc.europa.eu>
Cc: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Subject: RE: Eurosurveillance update request MS 20-01134

EXTERNAL EMAIL - Do not click on any links, open attachments or reply, unless you recognise the sender's email address (5.1.2e @rivm.nl) and believe the content is safe.

Dear 5.1.2e

Thank you for the edits. Please find attached our tracked version with all the requested changes.

Regarding the flowchart of the review process: we are now providing an additional figure. Our preference is for it to be a Supplementary figure (attached with the Disclaimer). However, if the editing style requires it to be a figure within the review, we are also attaching the figure pdf without captions.

Kind regards,

5.1.2e

5.1.2e 5.1.2e 5.1.2e
European Public Health Microbiology (EUPHEM) fellow

National Institute for Public Health and the Environment (RIVM)
Antonie van Leeuwenhoeklaan 9 | 3720 MA Bilthoven | The Netherlands

T 5.1.2e
M 5.1.2e
E 5.1.2e @rivm.nl
I <http://www.rivm.nl>

From: 5.1.5 <5.1.2e @ecdc.europa.eu>
Sent: 24 February 2021 11:32
To: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Cc: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Subject: Eurosurveillance update request MS 20-01134

Dear 5.1.2e and 5.1.2e
I hope that the edited version of the manuscript I sent last week arrived well to you.
If you are working on this still, could you please provide us with an update on when you think you can send us the next version?
Indeed, this will be helpful for planning from our side.
Wishing you a nice day,
Kind regards,
5.1.2e

From: 5.1.5 <5.1.2e @ecdc.europa.eu>
Sent: 20 February 2021 18:10
To: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Cc: 5.1.2e 5.1.2e <5.1.2e @rivm.nl>
Subject: Eurosurveillance edited version of manuscript MS 20-01134

Dear 5.1.2e and 5.1.2e

Apologies for the delay. This took a bit more time to edit than I anticipated, as it is a quite large manuscript.

Attached, you will find an edited version of your manuscript.

I kindly ask you to please go through this version to see if you are happy with the editing, and to please address the editorial comments, which can be viewed in the 'track-change' mode.

Please note that there are also comments after the main text, in the 'conflict of interest' and 'reference' sections. *For the references, please do not make changes using a reference software as this will interfere with our editing software, but please indicate any change you would like to implement in the answers to the bubble comments.*

If you agree with my edits, you can simply accept them, however if you make any new revisions, I kindly ask you to please keep these tracked so we can more easily see what has been done.

Overall, the comments should be quite straightforward, so we would prefer, if possible, to receive the next version of the manuscript by 9 am on Tuesday 23 February. Should you need more time however, please just inform us, so we can plan accordingly.

In the next round of editing, according to our routines, your manuscript will be checked by the Editor-in-chief, so there could be a few more comments at that stage. I will also be in touch regarding the designed figures.

Looking forward to further corresponding concerning the manuscript, I kindly ask you to please remain contactable this week as, all being well, we will attempt to finalise everything as soon as possible. I also remind below on our procedures for regular manuscripts, in case you wish to prepare your co-authors.

Kind regards,

5.1.2e

Procedures for regular manuscripts: *Once all issues regarding a given manuscript have been satisfactorily addressed subsequent to editing, the manuscript is finalised, and a final edited version of the manuscript is then sent by the editor to the corresponding author. At that final stage, we expect the corresponding author to ensure that all named authors see the final edited version, and, if all authors approve of this final edited version for publication, we kindly request the corresponding author to state in an email to us, that all named authors have seen and approve the final edited version for publication.*

From: 5.1.5 <5.1.2e@ecdc.europa.eu>

Sent: 19 February 2021 20:01

To: 5.1.2e 5.1.2e <5.1.2e@rivm.nl>

Cc: 5.1.2e 5.1.2e <5.1.2e@rivm.nl>

Subject: RE: Eurosurveillance further update MS 20-01134

Thanks 5.1.2e

I have almost finished but will try to send tomorrow morning because I would like to read one more time.

Have a nice weekend,

5.1.2e

From: 5.1.2e 5.1.2e <5.1.2e@rivm.nl>

Sent: 19 February 2021 17:28

To: 5.1.5 <5.1.2e@ecdc.europa.eu>; 5.1.2e 5.1.2e <5.1.2e@rivm.nl>

Subject: RE: Eurosurveillance further update MS 20-01134

EXTERNAL EMAIL - Do not click on any links, open attachments or reply, unless you recognise the sender's email address (5.1.2e@rivm.nl) and believe the content is safe.

Dear 5.1.2e

Thank you for the update. Have a nice evening and weekend as well,

5.1.2e

From: 5.1.5 <5.1.2e@ecdc.europa.eu>
Sent: vrijdag 19 februari 2021 17:14
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>
Subject: Eurosurveillance further update MS 20-01134

Dear 5.1.2e and 5.1.2e

I am making good progress with the work on the manuscript, but I still need to check a few things. I will be further in touch as soon as possible.

Wishing you a nice evening,

Kind regards,

5.1.2e



Eurosurveillance
Published by European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone + 5.1.2e / Fax 5.1.2e

www.eurosurveillance.org

Follow Eurosurveillance
on:



EUROSURVEILLANCE

Sent: 18 February 2021 13:49
To: 5.1.2e @rivm.nl' <5.1.2e@rivm.nl>; 5.1.2e @rivm.nl' <5.1.2e@rivm.nl>
Subject: Eurosurveillance update MS 20-01134

Dear 5.1.2e and dear 5.1.2e

I am currently working on your manuscript, and, all being well, I will try to send you an edited version by the end of the day on Friday 19 February.

Should I experience any delays however, I will send you an update about the situation around 2:30 pm tomorrow.

In the meantime, I take the opportunity of this email to inform on our procedures for regular manuscripts, in case you wish to prepare co-authors.

Kind regards,

5.1.2e

Procedures for regular manuscripts: Once all issues regarding a given manuscript have been satisfactorily addressed subsequent to editing, the manuscript is finalised, and a final edited version of the manuscript is then sent by the editor to the corresponding author. At that final stage, we expect the corresponding author to ensure that all named authors see the final edited version, and, if all authors approve of this final edited version for publication, we kindly request the corresponding author to state in an email to us, that all named authors have seen and approve the final edited version for publication.

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl *De zorg voor morgen begint vandaag*

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en *Committed to health and sustainability*

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.